GR1000247B - Σταθεραι λυοφιλιωμεναι διαμορφωσεις περιεχουσαι παραγοντας αναπτυξεως. - Google Patents

Σταθεραι λυοφιλιωμεναι διαμορφωσεις περιεχουσαι παραγοντας αναπτυξεως.

Info

Publication number
GR1000247B
GR1000247B GR880100618A GR880100618A GR1000247B GR 1000247 B GR1000247 B GR 1000247B GR 880100618 A GR880100618 A GR 880100618A GR 880100618 A GR880100618 A GR 880100618A GR 1000247 B GR1000247 B GR 1000247B
Authority
GR
Greece
Prior art keywords
constant
formulations containing
compositions
containing growing
growing agents
Prior art date
Application number
GR880100618A
Other languages
English (en)
Other versions
GR880100618A (en
Inventor
M Jonathan Cohen
L Amy Finkenaur
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Publication of GR880100618A publication Critical patent/GR880100618A/el
Publication of GR1000247B publication Critical patent/GR1000247B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Παρέχονται σταθεραί λυοφιλιωμέναι συνθέσεις περιλαμβάνουσαι πολυπεπτιδικούς παράγοντας αναπτύξεως και θήκες (σακκίδια με τα απαραίτητα) περιέχουσαι τας συνθέσεις. Οι συνθέσεις δύνανται να περιέχουν μέσα επεκτάσεως δια λυοφιλίωσιν και επίσης δύνανται να περιέχουν υδατο-διαλυτά πολυμερή δια να προσδώσουν ιξώδες εις ανασυσταθέν διάλυμα. ω
GR880100618A 1987-09-18 1988-09-16 Σταθεραι λυοφιλιωμεναι διαμορφωσεις περιεχουσαι παραγοντας αναπτυξεως. GR1000247B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9881787A 1987-09-18 1987-09-18

Publications (2)

Publication Number Publication Date
GR880100618A GR880100618A (en) 1989-06-22
GR1000247B true GR1000247B (el) 1992-05-12

Family

ID=22271044

Family Applications (1)

Application Number Title Priority Date Filing Date
GR880100618A GR1000247B (el) 1987-09-18 1988-09-16 Σταθεραι λυοφιλιωμεναι διαμορφωσεις περιεχουσαι παραγοντας αναπτυξεως.

Country Status (9)

Country Link
EP (1) EP0308238A1 (el)
JP (1) JPH01121223A (el)
KR (1) KR890004721A (el)
AU (1) AU2223688A (el)
DK (1) DK516788A (el)
GR (1) GR1000247B (el)
NZ (1) NZ226170A (el)
PT (1) PT88538A (el)
ZA (1) ZA886943B (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
JP2865320B2 (ja) * 1989-08-07 1999-03-08 株式会社資生堂 固型化粧料組成物
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
AU7312291A (en) * 1990-02-13 1991-09-03 Gere S. Dizerega Peritoneal induced medicaments
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DK148790D0 (da) * 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
JP2926930B2 (ja) * 1990-08-09 1999-07-28 富士ゼロックス株式会社 静電記録装置
US5197973A (en) * 1990-12-14 1993-03-30 Creative Biomolecules, Inc. Synthetic bioadhesive
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP0637450A3 (en) * 1993-08-04 1995-04-05 Collagen Corp Method and composition for resuscitation of hereditary tissue.
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
SE9400036D0 (sv) * 1994-01-10 1994-01-10 Pharmacia Ab Low modecular weight hyaluronic acid
EP0782850A4 (en) * 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU4027601A (en) * 1995-07-11 2001-07-26 Snow Brand Milk Products Co., Ltd. Lyophilized HGF preparations
GB9608222D0 (en) * 1996-04-20 1996-06-26 Innovative Tech Ltd Dehydrated hydrogels
US5989269A (en) 1996-08-30 1999-11-23 Vts Holdings L.L.C. Method, instruments and kit for autologous transplantation
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
AU6267798A (en) * 1997-02-07 1998-08-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
JP2002522168A (ja) 1998-08-14 2002-07-23 ベリゲン トランスプランタツィオーン セルビス インテルナツィオナル （フォウテーエスイー） アーゲー 軟骨細胞移植のための方法、器具および材料
EP1161257A2 (en) * 1999-03-17 2001-12-12 Novartis AG Pharmaceutical compositions comprising tgf-beta
GB9914412D0 (en) * 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US20030068416A1 (en) * 2001-09-24 2003-04-10 Wilson Burgess Method of lyophylization to reduce solvent content and enhance product recovery
TWI436789B (zh) * 2008-01-21 2014-05-11 Intervet Int Bv 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包
US8734854B2 (en) * 2009-07-09 2014-05-27 Orogen Biosciences Inc. Process for removing growth factors from platelets
US9757418B1 (en) 2009-07-09 2017-09-12 Pgfx Patent Holdings, Llc Process for removing growth factors from platelets
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP3287139B1 (en) 2015-04-21 2021-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and injection powder
US20220061310A1 (en) * 2018-12-28 2022-03-03 Excel Med, Llc Method for stabilizing bioactivity of growth factor
CN113975193A (zh) * 2021-11-12 2022-01-28 广州科妍化妆品有限公司 一种冻干面膜及其制备方法
CN117205162B (zh) * 2023-09-12 2024-06-25 上海腾瑞制药股份有限公司 一种重组人酸性成纤维细胞生长因子冻干制剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US4469228A (en) * 1983-05-31 1984-09-04 Schering Corporation Interferon kit
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration

Also Published As

Publication number Publication date
GR880100618A (en) 1989-06-22
KR890004721A (ko) 1989-05-09
EP0308238A1 (en) 1989-03-22
PT88538A (pt) 1989-07-31
DK516788D0 (da) 1988-09-16
JPH01121223A (ja) 1989-05-12
ZA886943B (en) 1990-05-30
NZ226170A (en) 1990-07-26
DK516788A (da) 1989-03-19
AU2223688A (en) 1989-03-23

Similar Documents

Publication Publication Date Title
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DK516788A (da) Stabile lyophiliserede praeparater indeholdende vaekstfaktorer
AU7489687A (en) Translation of mrna
ES552627A0 (es) Procedimiento para la preparacion de carbamatos de fenilo
BG102708A (en) 4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
FI892454A0 (fi) Nya bensimidazolderivat, foerfarande foer framstaellning av desamma och farmaceutisk komposition innehaollande desamma.
DK164479C (da) Sucralfatsuspension og fremgangsmaade til fremstilling af denne
FI875220A7 (fi) Mikrobeja tuhoavia proteiineja, niitä sisältäviä koostumuksia ja niiden käyttö.
FI871983A7 (fi) Perfluoripolyeettereitä, jotka eivät sisällä peroksidihappea ja joiden perfluoripolyeetteriketjussa on perfluoriepoksiryhmiä, sekä niiden johdannaisia.
DK648088A (da) Stabilisering af antistoffer
MX9708426A (es) Polipeptido hk2 de variante estable.
ZA886903B (en) Stabilisation of therapeutically active proteins in pharmaceutical preparations
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
ATE92955T1 (de) Stabilisierte protoplasten.
IL84551A0 (en) Peptides,their preparation and pharmaceutical compositions containing them
ES2060944T3 (es) Derivados de 2,5,6,7-tetranor-4,8-inter-m-fenileno de pgi2 (prostaglandina i2).
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE69228031D1 (de) Ch0ndromodulin-II Protein
GR1000098B (el) Παραγωγα διοξαζοκινης, παρασκευη των και συνθεσεις που τα περιεχουν.
ES289145U (es) Cabeza de combate
DE3853710D1 (de) Siliciumatome und Imidogruppen enthaltende Oligomere, härtbare Zusammensetzungen und deren Herstellung.
ES2125849T3 (es) 1-dimetilcarbamoil-3-sustituido-5-sustituido-1h-1,2,4-triazoles.
SU1538846A1 (ru) Лазерный материал
IT1177378B (it) Vettore plasmidico psm112 ad espressione in bacillus subtilis